I. COMMENCED TRADING IN JUNE
Company (Symbol) |
Date Filed |
Date Comm. |
Shares/ Units (M) |
Price |
Shares Out (M) |
Lead, Other Underwriters |
Gross ($M) |
Net ($M) |
INITIAL OFFERINGS | ||||||||
VaxGen Inc. (VXGN) |
5/7 |
6/30 |
3.1S |
$13 |
10.8 |
Prudential Securities; Punk, Ziegel & Co. |
$40.3 |
$37.5E |
FOLLOW-ON OFFERINGS | ||||||||
Alliance Pharmaceutical Corp. (ALLP) |
4/15 |
6/11 |
9.5 |
$2.45 |
33.2 |
Cruttendon Roth Inc. |
$23.275 |
$22.1E |
TOTAL: $63.6M | ||||||||
II. FILED AND PENDING
Company (Symbol) |
Date Filed |
Shares/ Units (M) |
Price Range |
Shares Out (M) |
Lead, Other UWs |
Value (M) |
||
INITIAL OFFERINGS | ||||||||
BioMarin1 Pharmaceutical Inc. (Proposed NASDAQ symbol:BMRN) |
5/4 |
N/A |
N/A |
N/A |
U.S. Bancorp Piper Jaffray; Vontobel Securities Ltd.; Schroders Securities Co. Ltd.; Leerink Swann & Company |
N/A |
||
Biopure Corp.2 (Proposed NASDAQ symbol: BPUR) |
5/19 |
N/A |
N/A |
N/A |
J.P. Morgan & Co.; Adams, Harkness & Hill Inc.; Robert W. Baird& Co. |
N/A |
||
|
1 BioMarin's registration statement leaves blank information on the number of shares to be offered, number outstanding following the offering and price per share. The offering is international the company has applied for listings on both the Nasdaq National Market and the Swiss Exchange. The maximum aggregate price, for the purpose of determining SEC fees, is $58.5 million. 2 Biopure's registration statement leaves blank information on the number of shares to be offered, number outstanding following the offering and price per share. The maximum aggregate price, for the purpose of determining SEC fees, is $86.25 million. N/A = Information not available. FOLLOW-ON OFFERINGS | ||||||||
Angiotech Pharmaceuticals Inc. (TSE:ANP)1 |
6/17 |
N/A |
N/A |
11.8 (pre- offering) |
Levasque Beaubien Geoffren Inc.; Loewen, Ondaatje, McCutcheon Ltd. |
C$15M (US$10.2)* |
||
Aquila Biopharmaceuticals Inc.2 (AQLA) |
6/4 |
0.75 |
$2 |
6.9 |
- |
$1.5 |
||
NeoTherapeutics Inc. (NEOT) |
6/18 |
3.5 |
$13 |
10.2 |
Joseph Charles & Associates |
$45.5 |
||
Ribozyme Pharmaceuticals Inc. (RZYM) |
3/26 |
1.8 |
$5 |
11 |
- |
$9 |
||
|
* Canadian dollars converted to U.S. dollars at a rate of C$1.00=US$0.68. 1 Angiotech filed a prospectus to raise C$15M. Based on the June 17 closing price of $11.25 per share, the company would have to sell 1.33M shares to meet that target. 2 Aquila registered 750,000 shares to be sold in a direct limited placement to be negotiated by the company. | ||||||||